Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00084877 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: triapine
DRUG: irinotecan hydrochloride
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)